| INSMED INC. DL-,01 |
| USA |
| Gesundheit |
| US4576693075 / A1JJA3 |
| IM8N (Frankfurt) / INSM (NASDAQ) |
| FRA:IM8N, ETR:IM8N, IM8N:GR, NASDAQ:INSM |
| - |
| https://insmed.com/ |
|
Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases. Its current portfolio includes an approved treatment for Mycobacterium avium complex lung disease, along..
>Volltext.. |
| 24517.92 Mio. EUR |
| 24167.59 Mio. EUR |
| 1382.19 Mio. EUR |
| -551.94 Mio. EUR |
| -550.8 Mio. EUR |
| -2.56 EUR |
| 681.91 Mio. EUR |
| 360.68 Mio. EUR |
| -541.72 Mio. EUR |
| 1.92 |
| 252.15% |
| 47.01% |
| - |
| - |
| - |
| - |
| INSMED |
| 19.11.26 |
|